The estimated Net Worth of Biopharma Partners Iii Lpal... is at least 12.5 千$ dollars as of 5 February 2014. Biopharma Lpal owns over 112,817 units of Cara Therapeutics Inc stock worth over 12,531$ and over the last 11 years Biopharma sold CARA stock worth over 0$.
Biopharma has made over 1 trades of the Cara Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Biopharma bought 112,817 units of CARA stock worth 1,240,987$ on 5 February 2014.
The largest trade Biopharma's ever made was buying 112,817 units of Cara Therapeutics Inc stock on 5 February 2014 worth over 1,240,987$. On average, Biopharma trades about 112,817 units every 0 days since 2014. As of 5 February 2014 Biopharma still owns at least 43,212 units of Cara Therapeutics Inc stock.
You can see the complete history of Biopharma Lpal stock trades at the bottom of the page.
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over 25,200,591$ worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth 19,406,983$ . The most active insiders traders include Edward Hurwitz、Martin Vogelbaum、Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of 5,343$. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth 1,452$.
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Cara Therapeutics Inc executives and other stock owners filed with the SEC include: